DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Allo-hMSCs; Ambrisentan; Autologous (self) mononuclear cells derived from umbilical cord blood; Autologous Human Placental Cord Blood Mononuclear Cells; Autologous Umbilical Cord Blood; Autologous cell-based delivery; Bosentan; C-kit+ cells; Curosurf; Erythropoetin; Longeveron Mesenchymal Stem Cells; METHYLPREDNISOLONE SODIUM SUCCINATE; MPC; Maternal Hyperoxygenation; Maternal hyperoxygenation; Methylprednisolone; Metyyliprednisoloninatriumsuksinaatti; Nitrogen; Normal saline; Oxandrolone; Procedure: Stage II Surgical repair; Rexlemestrocel-L; Sham; Sildenafil; Solu-Medrol; Solu-medrol; Tracleer; Vitamin C

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01883076 (ClinicalTrials.gov)	May 15, 2013	11/6/2013	Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome	Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome	Hypoplastic Left Heart Syndrome	Biological: autologous cell-based delivery	Timothy J Nelson, MD, PhD	University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospitals and Clinics of Minnesota;Children's Hospital Los Angeles;Children's Hospital Colorado;Mayo Clinic	Active, not recruiting	N/A	18 Months	All	30	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01883076
(ClinicalTrials.gov)

May 15, 2013

11/6/2013

Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome

Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome

Hypoplastic Left Heart Syndrome

Biological: autologous cell-based delivery

Timothy J Nelson, MD, PhD

University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospitals and Clinics of Minnesota;Children's Hospital Los Angeles;Children's Hospital Colorado;Mayo Clinic

Active, not recruiting

N/A

18 Months

All

Phase 1

United States